NCT06212960View on ClinicalTrials.gov

Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 28, 2023

Primary Completion Date

February 26, 2024

Study Completion Date

March 21, 2024

Conditions
Glabellar Lines
Interventions
BIOLOGICAL

DWP712

Clostridium botulinum Toxin

BIOLOGICAL

BOTOX®

Clostridium botulinum Toxin

Trial Locations (1)

Unknown

Chung-Ang University Hosptial, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY